RNAC FY 2023 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$218M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M-76.5% YoY

Gross Profit

$26M100.0% margin

Operating Income

-$86M-332.3% margin

Net Income

-$220M-844.9% margin

EPS (Diluted)

$-49.76

Cash Flow

Operating Cash Flow

-$51M

Free Cash Flow

-$51M

Stock-Based Comp.

$23M

Balance Sheet

Total Assets

$305M

Total Liabilities

$745M

Stockholders' Equity

-$440M

Cash & Equivalents

$77M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$111M	-76.5%
Gross Profit	$26M	$109M	-76.1%
Operating Income	-$86M	$15M	-694.4%
Net Income	-$220M	$35M	-721.0%